OBJECTIVE: To explore the therapeutic effects of sequential intensified conditioning regimen followed by @entity2132 (GVL) induction in allogeneic hematopoietic stem cell transplantation (allo-HSCT) for refractory advanced @entity3052 ( @entity3052 ). METHODS: A total of 72 @entity1 with refractory @entity3052 undergoing allo-HSCT from May 2001 to June 2013 were enrolled in this prospective study. Intensified conditioning included @entity3118 + @entity2592 plus total body irradiation + @entity786 + @entity2879 . @entity205 was withdrawn rapidly in a stepwise fashion if @entity1 who did not experience @entity2132 ( @entity2132 ) at Day + 30 post-transplantation. Donor lymphocytes were infused in @entity1 without grade II or more than grade II @entity2132 at Day + 60 post-transplantation. RESULTS: The median follow-up time was 655 (1-4 200) d post-transplantation. Except for one died of @entity281 and one died of regimen-related @entity137 (RRT), the other 70 @entity1 achieved complete remission at the time of neutrophil reconstitution. The mortality of RRT was 1.4% (1/72). The 1-year cumulative incidence of @entity2132 and 2-year incidence of chronic GVHD (cGVHD) post-transplantation were 60.7%    5.0% and 58.5%    4.7%. The 5-year cumulative incidence of relapse post-transplantation was 29.6%    6.6%. The 5-year non-relapse mortality was 28.8%    6.0%. The 5-year overall and disease-free survival were 51.0%    6.5% and 49.9%    6.4%. Multivariate analysis revealed that donor lymphocyte infusion, cGVHD and bone marrow blasts at Day 0 were independent prognostic factors for relapse (HR (95% CI): 0.042 (0.007-0.688), 0.009 (0.003-0.345), 3.385 (1.451-7.899)) and survival (HR (95% CI): 0.315 (0.146-0.621), 0.416 (0.200-0.866), 1.332 (1.158-1.533)). CONCLUSION: The strategy of sequential intensified conditioning followed by GVL induction has an acceptable @entity137 profile, and could decrease the relapse rate and improve the survival for refractory @entity3052 .

[Sequential intensified conditioning followed by graft-versus-leukemia induction could prevent relapse of refractory XXXX after allogeneic hematopoietic stem cell transplantation].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity2592 :: ('MESH:D003561', 'Chemical') :: ['cytarabine'] @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myeloid leukemia', 'AML'] @entity3118 :: ('MESH:C024352', 'Chemical') :: ['fludarabine'] @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide'] @entity2132 :: ('MESH:D006086', 'Disease') :: ['graft-versus-1eukemia', 'acute graft-versus-host disease', 'aGVHD'] @entity205 :: ('MESH:D016572', 'Chemical') :: ['Cyclosporine A'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']
@entity3052 :: (MESH:D015470,Disease) :: ['acute myeloid leukemia']
